Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Genetics Increases Number of Shares, Targeted Proceeds for IPO

NEW YORK (GenomeWeb News) – Atossa Genetics has increased to 1.3 million the number of shares it plans to offer in its initial public offering, the firm said in a document filed with the US Securities and Exchange Commission on Friday.

The Seattle-based firm had previously targeted an offering of 1.2 million shares of its common stock. It also said last week that it needs to raise at least $6.25 million in gross proceeds from the offering in order to get listed on the Nasdaq Capital Market under ticker symbol "ATOS". It previously had said it needed to raise a minimum of $6 million.

The company continues to expect the share price on its IPO to be between $4 and $6. Dawson James Securities is listed as the underwriter on the offering.

Atossa announced earlier this month a marketing deal for its Mammary Aspirate Specimen Cytology Test System, or MASCT, and the acquisition of the assets of intraductal diagnostic and therapeutic company Acueity Healthcare. Last month, it disclosed a deal to provide access to its tests to providers and patients in managed healthcare plan MultiPlan's networks.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.